East Asian Economic Review

Korea Institute for International Economic Policy (대외경제정책연구원)
권호 표지
DOI QR코드

DOI QR Code

The Health Impact of, and access to, New Drugs in Korea

  • Lichtenberg, Frank R. (Columbia University, National Bureau of Economic Research, and CESifo)
  • Received : 2020.04.15
  • Accepted : 2020.06.02
  • Published : 2020.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

We perform an econometric assessment of the role that pharmaceutical innovation-the introduction and use of new drugs-has played in improving the health of Koreans, by investigating whether diseases for which more new drugs were launched had larger subsequent increases in longevity and smaller subsequent increases in hospitalization. Drugs launched during 1993-2012 are estimated to have increased mean age at death from all diseases by 1.71 years between 1995 and 2015 and 1.09 years between 2005 and 2015. We also estimate that new drugs increased the five-year relative survival rate from all cancers combined by 23.2 percentage points-78.5% of the total increase-between 1993-1995 and 2011-2015, and that new drugs launched during 2008-2010 reduced the number of hospital days in 2017 by 13.0 million. If the drugs launched during 2003-2012 had had no effect on other medical expenditure in 2015, the cost per life-year gained would not have exceeded 6332 USD. Therefore, even if we ignore the effect of new drugs on hospital utilization, the drugs launched during 2003-2012 were very cost-effective, overall. When reduced hospital utilization is accounted for, the evidence indicates that, in the long run, pharmaceutical innovation was cost-saving as well as life-year saving.

Keywords

References

  1. Aghion, P. and P. Howitt. 2005. Growth with Quality-Improving Innovations: An Integrated Framework. In Aghion, P. and S. N. Durlauf. (eds.) Handbook of Economic Growth. vol. 1, part A, Amsterdam: Elsevier. pp. 67-110.
  2. Bertram, M. Y., Lauer, J. A., De Joncheere, K., Edejer, T., Hutubessy, R., Kieny, M. P. and S. R. Hill. 2016. "Cost-Effectiveness Thresholds: Pros and Cons," Bulletin World Health Organization, vol. 94, no. 12, pp. 925-930. https://doi.org/10.2471/BLT.15.164418
  3. Bils, M. 2004. Measuring the Growth from Better and Better Goods. NBER Working Paper, no. 10606.
  4. Bresnahan, T. F. and R. J. Gordon. 1996. The Economics of New Goods. Chicago: University of Chicago Press.
  5. Centre National Hospitalier d'Information sur le Medicament. 2019. Theriaque database. (accessed January 21, 2020)
  6. Dorsey, E. R., de Roulet, J., Thompson, J. P., Reminick, J. I., Thai, A. White-stellato, Z., Beck, C. A., George, B. P., and H. Moses III. 2010. "Financial Anatomy of Biomedical Research, 2003-2008," Journal of the American Medical Association, vol. 303, no. 2, pp. 137-143. https://doi.org/10.1001/jama.2009.1987
  7. Grossman, G. M. and E. Helpman. 1991. Innovation and Growth in the Global Economy. Cambridge: MIT Press.
  8. Hausman, J. 2001. "Mismeasured Variables in Econometric Analysis: Problems from the Right and Problems from the Left," Journal of Economic Perspectives, vol. 15, no. 4, pp. 57-67. https://doi.org/10.1257/jep.15.4.57
  9. International Federation of Pharmaceutical Manufacturers & Associations. 2017. The Pharmaceutical Industry and Global Health: Facts and Figures 2017. (accessed January 21, 2020)
  10. Jones, C. I. 1998. Introduction to Economic Growth. New York: W.W. Norton.
  11. Jones, C. I. 2002. "Sources of U.S. Economic Growth in a World of Ideas," American Economic Review, vol. 92, no. 1, pp. 220-239. https://doi.org/10.1257/000282802760015685
  12. Jovanovic, B. and Y. Yatsenko. 2012. "Investment in Vintage Capital," Journal of Economic Theory, vol. 147, no. 2, pp. 551-569. https://doi.org/10.1016/j.jet.2010.10.017
  13. Jung, K.-W., Won, Y.-J., King, H.-J., Lee, E. S. and The Community of Population-Based Regional Cancer Registries. 2018. "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015," Cancer Research and Treatment, vol. 50, no. 2, pp. 303-316. https://doi.org/10.4143/crt.2018.143
  14. Koc, C. 2004. "The Productivity of Health Care and Health Production Functions," Health Economics, vol. 13, no. 8, pp. 739-747. https://doi.org/10.1002/hec.855
  15. Kolata, G. 2019. Surgery for Blocked Arteries Is Often Unwarranted, Researchers Find. New York Times, vol. 169, no. 58,514, Section A, p. 19. (Print November, 17, Online November, 16)
  16. Lichtenberg, F. R. 2009. "Have Newer Cardiovascular Drugs Reduced Hospitalization? Evidence from Longitudinal Country-Level Data on 20 OECD Countries, 1995-2003," Health Economics, vol. 18, no. 5, pp. 519-534. https://doi.org/10.1002/hec.1382
  17. Lichtenberg, F. R. 2014a. "Has Medical Innovation Reduced Cancer Mortality?" CESifo Economic Studies, vol. 60, no. 1, pp. 135-177. https://doi.org/10.1093/cesifo/ift014
  18. Lichtenberg, F. R. 2014b. "The Impact of Pharmaceutical Innovation on Longevity and Medical Expenditure in France, 2000-2009," Economics and Human Biology, vol. 13, pp. 107-127. https://doi.org/10.1016/j.ehb.2013.04.002
  19. Lichtenberg, F. R. 2014c. "Pharmaceutical Innovation and Longevity Growth in 30 Developing and High-income Countries, 2000-2009," Health Policy and Technology, vol. 3, no. 1, pp. 36-58. https://doi.org/10.1016/j.hlpt.2013.09.005
  20. Lichtenberg, F. R. 2014d. "The Impact of Pharmaceutical Innovation on Disability Days and the Use of Medical Services in the United States, 1997-2010," Journal of Human Capital, vol. 8, no. 4, pp. 432-480. https://doi.org/10.1086/679110
  21. Lichtenberg, F. R. 2018. "The Impact of New Drug Launches on Hospitalization in 2015 for 67 Medical Conditions in 15 OECD Countries: a Two-Way Fixed-Effects Analysis," Forum for Health Economics & Policy, vol. 21, no. 2. (accessed January 21, 2020)
  22. National Cancer Institute. 2012. Long-Term Trial Results Show No Mortality Benefit from Annual Prostate Cancer Screening. (accessed December 7, 2019)
  23. National Cancer Institute. 2019. Enhancing Drug Discovery and Development. (accessed December 7, 2019)
  24. National Institute for Health and Care Excellence. 2019. The Guidelines Manual: Assessing cost effectiveness. (accessed December 7, 2019)
  25. Nordhaus, W. D. 2005. "Irving Fisher and The Contribution of Improved Longevity to Living Standards," American Journal of Economics and Sociology, vol. 64, no. 1, pp. 367-392. https://doi.org/10.1111/j.1536-7150.2005.00367.x
  26. Organisation for Economic Co-operation and Development (OECD). 2019a. OECD Health Statistics 2019 Definitions, Sources and Methods Hospital discharges by diagnostic categories. (accessed March 21, 2020)
  27. Organisation for Economic Co-operation and Development (OECD). 2019b. International shortlist for hospital morbidity tabulation. (accessed March 21, 2020)
  28. Organisation for Economic Co-operation and Development (OECD). 2019c. OECD Health Statistics database. (accessed December 7, 2019)
  29. Sampat, B. and F. R. Lichtenberg. 2011. "What are the Respective Roles of the Public and Private Sectors in Pharmaceutical Innovation?" Health Affairs, vol. 30, no. 2, pp. 332-339. https://doi.org/10.1377/hlthaff.2009.0917
  30. Statistics Korea. 2010. 2009 Life Tables for Korea. (accessed January 21, 2020)
  31. U.S. Department of Veterans Affairs, Health Economics Resource Center. 2019. Budget Impact Analysis. (accessed January 21, 2020)
  32. World Health Organization (WHO). 2019. Cause of Death Query online database. (accessed January 21, 2020)
  33. Yang, S., Khang, Y.- H., Harper, S., Davey Smith G., Leon, D. A. and J. Lynch. 2010. "Understanding the rapid increase in life expectancy in South Korea," American Journal of Public Health, vol. 100, no. 5, pp. 896-903. https://doi.org/10.2105/AJPH.2009.160341